CC
COGT icon

Commodore Capital’s Cogent Biosciences COGT Stock Holding History

Commodore Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118M Buy
3,050,000
+161,993
+6% +$5.67M 7.03% 4
2026
Q1 		$111M Buy
2,888,007
+691,162
+31% +$25.5M 6.43% 4
2025
Q4 		$78M Sell
2,196,845
-5,053,155
-70% -$142M 5.19% 6
2025
Q3 		$104M Buy
7,250,000
+4,938,836
+214% +$58.5M 5.08% 4
2025
Q2 		$16.6M Sell
2,311,164
-6,581,652
-74% -$36.5M 1.17% 23
2025
Q1 		$53.3M Buy
8,892,816
+2,011,187
+29% +$15.8M 3.93% 12
2024
Q4 		$53.7M Sell
6,881,629
-658,301
-9% -$6.56M 3.93% 10
2024
Q3 		$81.4M Sell
7,539,930
-2,198,070
-23% -$21.4M 5.09% 7
2024
Q2 		$82.1M Buy
9,738,000
+3,313,000
+52% +$25.1M 5.6% 7
2024
Q1 		$43.2M Buy
6,425,000
+858,974
+15% +$5.31M 2.89% 12
2023
Q4 		$32.7M Hold
5,566,026
– – 2.86% 13
2023
Q3 		$54.3M Hold
5,566,026
– – 6.34% 5
2023
Q2 		$65.9M Buy
5,566,026
+793,605
+17% +$9.1M 7.41% 5
2023
Q1 		$51.5M Buy
4,772,421
+452,481
+10% +$5.79M 7.84% 4
2022
Q4 		$49.9M Hold
4,319,940
– – 7.53% 3
2022
Q3 		$64.5M Sell
4,319,940
-624,768
-13% -$8.56M 10.36% 1
2022
Q2 		$44.6M Buy
4,944,708
+1,443,940
+41% +$9.86M 9.43% 3
2022
Q1 		$26.2M Buy
3,500,768
+1,219,453
+53% +$8.49M 5.86% 8
2021
Q4 		$19.6M Buy
2,281,315
+368,804
+19% +$3.21M 4.53% 8
2021
Q3 		$16.1M Buy
1,912,511
+544,929
+40% +$4.18M 4.24% 8
2021
Q2 		$11.1M Buy
1,367,582
+98,387
+8% +$831K 3.86% 9
2021
Q1 		$11.1M Buy
1,269,195
+509,170
+67% +$4.9M 4.44% 7
2020
Q4 		$8.54M Buy
+760,025
New +$8.35M 4.64% 8

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Commodore Capital's COGT Position: Q2 2026 in Review

Commodore Capital increased its Cogent Biosciences (COGT) stake by 5.6% in Q2 2026, buying an estimated $5.67M and bringing the position to 3,050,000 shares worth $118M. The position accounts for 7.03% of the portfolio, ranked #4.

Commodore Capital first reported a position in COGT in Q4 2020 and has held it in 23 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Commodore Capital held 3,050,000 shares of Cogent Biosciences worth $118M as of Q2 2026.
  • Commodore Capital bought 161,993 Cogent Biosciences shares in Q2 2026, an estimated $5.67M.
  • Cogent Biosciences made up 7.03% of Commodore Capital's portfolio in Q2 2026, its #4 holding.
  • Commodore Capital first reported a position in Cogent Biosciences in Q4 2020 and has held it in 23 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.